N@N

Haemacure announces its presentation at the Rodman &; Renshaw 11th Annual Healthcare Conference

_{//health-fitness.news-articles.net/content/2009/ .. n-renshaw-11th-annual-healthcare-conference.html}
^{Published in Health and Fitness on Tuesday, September 8th 2009 at 13:50 GMT by Market Wire}  

 HAE: TSX MONTREAL, Sept. 8 /CNW Telbec/ - Haemacure Corporation (TSX:HAE), a specialty bio-therapeutics company, announces that its Chairman and CEO, Mr. Joseph Galli, will present at the Rodman & Renshaw 11th Annual Healthcare Conference on September 9, 2009 at 2:00 p.m. at the New York Palace Hotel in New York. The presentation will be live by webcast at[ http://www.wsw.com/webcast/rrshq15/hae.to ]. Please visit the site at least five minutes prior to start time for instructions. About Haemacure Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical haemostats. Haemacure's proprietary, lead product candidate is a fibrin sealant in late-stage clinical trials. Haemacure's proprietary, second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on the use of fibrin sealant in aesthetics, adhesion prevention, combination with biomaterials, drug delivery, regenerative medecine, skin graft fixation for burn injuries, and wound healing. Forward-looking Statements Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements. 

For further information: Joseph Galli, Chairman and CEO, Haemacure Corporation, (514) 990-7074, [ jgalli@haemacure.ca ]; Gilles Lemieux, Secretary, Haemacure Corporation, (514) 282-3350 ext. 22, [ glemieux@haemacure.ca ]; [ www.haemacure.com ]